Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow JNJ
Johnson & Johnson (JNJ) Revenue growth
Johnson & Johnson's revenue growth over the twelve months to 30 September 2026 was 7.80%, up 1.8 percentage points from fiscal 2025 (6.05%). Over the past ten years it has ranged from −5.73% (fiscal 2015) to 6.71% (fiscal 2018); the current reading is higher than 73% of that period. That is above the Drug Manufacturers General industry median of 6.66% and below the Healthcare sector median of 8.27%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 6.05% | 1.75 |
| FY2024 | 4.30% | (2.16) |
| FY2023 | 6.46% | 4.87 |
| FY2022 | 1.59% | 6.24 |
| FY2021 | −4.65% | (5.29) |
| FY2020 | 0.64% | 0.05 |
| FY2019 | 0.59% | (6.12) |
| FY2018 | 6.71% | 0.37 |
| FY2017 | 6.34% | 3.75 |
| FY2016 | 2.59% | 8.32 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 5.86% | (0.74) |
| Jun 2026 | 6.60% | (3.31) |
| Mar 2026 | 9.91% | 0.83 |
| Dec 2025 | 9.08% | 2.31 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| LLY Eli Lilly and Company compare | 49.6% |
| ABBV AbbVie Inc. compare | 10.4% |
| AMGN Amgen Inc. compare | 9.10% |
| AZN AstraZeneca PLC compare | 8.61% |
| JNJ Johnson & Johnson | 7.80% |
| GILD Gilead Sciences, Inc. compare | 5.52% |
| MRK Merck & Co., Inc. compare | 4.64% |
| NVS Novartis AG compare | 2.73% |
| PFE Pfizer Inc. compare | −0.21% |
| Drug Manufacturers General industry median | 6.66% |
| Healthcare sector median | 8.27% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement